Results 41 to 50 of about 4,308 (211)

Improved pharmacokinetics of tenofovir ester prodrugs strengthened the inhibition of HBV replication and the rebalance of hepatocellular metabolism in preclinical models

Frontiers in Pharmacology, 2022
Tenofovir (TFV) ester prodrugs, a class of nucleotide analogs (NAs), are the first-line clinical anti-hepatitis B virus (HBV) drugs with potent antiviral efficacy, low resistance rate and high safety.
Xiaodan Hong, Zuhuan Cai, Fang Zhou, Xiaoliang Jin, Guangji Wang, Bingchen Ouyang, Jingwei Zhang   +6 more
doaj   +1 more source

Serum LNG (pg/mL) in TFV/LNG continuous IVR Users (n = 18) and in TFV/LNG interrupted IVR users IVR users (n = 17).

, 2022
Serum LNG (pg/mL) in TFV/LNG continuous IVR Users (n = 18) and in TFV/LNG interrupted IVR users IVR users (n = 17).
Nazita Yousefieh (751094), Betsy C. Herold (9634748), Leila Cochon (12621924), Elizabeth Tolley (5945897), Andrea R. Thurman (5286005), Vivian Brache (200187), Melissa Peet (13933074), Urvi Parikh (346278), Jill L. Schwartz (11434312), Susan Ju (5940782), Louise A. Ouattara (12210068), Gustavo F. Doncel (339755), Raina N. Fichorova (7251227), David W. Erikson (13933077), Homaira Hanif (10885137), Meredith R. Clark (11434306), Terry Jacot (5940767), Mark A. Marzinke (9579575), Neelima Chandra (5465411)   +18 more
core   +1 more source

Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings.

PLoS ONE, 2019
Recent data support that the vaginal microbiota may alter mucosal pharmacokinetics (PK) of topically delivered microbicides. Our team developed an intravaginal ring (IVR) that delivers tenofovir (TFV) (8-10 mg/day) alone or with levonorgestrel (LNG) (20 ...
Andrea Ries Thurman, Jill L Schwartz, Jacques Ravel, Pawel Gajer, Mark A Marzinke, Nazita Yousefieh, Sharon M Anderson, Gustavo F Doncel   +7 more
doaj   +1 more source

Ticari Bankaların Etkinliklerinin VZA ve Malmquist TFV Endeksi ile İncelenmesi

Atatürk Üniversitesi İktisadi ve İdari Bilimler Dergisi, 2020
The aim of this study is to analyze the efficiency and productivity of commercial banks operating in Turkey. For this purpose, the efficiency and productivity of 23 commercial banks operating in Turkey, whose continuous data of the years 2005-2018 were reached, have been analyzed through DEA and Malmquist Total Factor Productivity Analysis.
ŞAHİN, Faruk, ÖZDEMİR, Dilek
openaire   +4 more sources

Mucosal concentrations of TFV and TFV-DP based on community state type (CST) at end of treatment (visit 7) for TFV and TFV/LNG IVR users combined.

, 2019
Mucosal concentrations of TFV and TFV-DP based on community state type (CST) at end of treatment (visit 7) for TFV and TFV/LNG IVR users combined.
Mark A. Marzinke (734979), Nazita Yousefieh (751094), Andrea Ries Thurman (5465414), Jill L. Schwartz (200175), Sharon M. Anderson (6714311), Jacques Ravel (5502), Gustavo F. Doncel (339755), Pawel Gajer (178443)   +7 more
core   +1 more source

Serum TFV and TFV-DP concentration versus time.

, 2013
Serum TFV (panel A) and PBMC TFV-DP (panel B) concentration versus time plots are shown for the observed 8 hour interval following a dose in clinic according to dosing regimen. Median with asymmetric upper and lower quartiles is shown.
Karen Patterson (278030), Craig Hoesley (278027), Vijayanand Guddera (278026), Namandje N. Bumpus (278036), Clemensia Nakabiito (224531), Barbra A. Richardson (172638), Alexandra M. Minnis (278032), Kailazarid Gomez (278035), Sharavi Gandham (278034), Lydia Soto-Torres (232208), Beatrice A. Chen (278025), Robert Salata (278029), Craig W. Hendrix (232212), Jessica Justman (278028)   +13 more
core   +1 more source

Hepatitis B surface antigen reduction as a result of switching from long‐term entecavir administration to tenofovir

JGH Open, 2020
Background and Aim Loss of hepatitis B surface antigen (HBsAg) is an important goal in the treatment of chronic hepatitis B. We investigated whether switching from long‐term entecavir (ETV) administration to tenofovir (TFV) (tenofovir alafenamide [TAF ...
Nobuharu Tamaki, Masayuki Kurosaki, Sakura Kirino, Koji Yamashita, Leona Osawa, Shuhei Sekiguchi, Yuka Hayakawa, Wan Wang, Mao Okada, Mayu Higuchi, Kenta Takaura, Chiaki Maeyashiki, Shun Kaneko, Yutaka Yasui, Kaoru Tsuchiya, Hiroyuki Nakanishi, Jun Itakura, Yuka Takahashi, Nobuyuki Enomoto, Namiki Izumi   +19 more
doaj   +1 more source

Volume-averaged TFV and TFV-DP concentrations vs. time after enema application in different compartments.

, 2017
Enema retention times are 5, 10, or 20 minutes (blue, green and red lines). A small sized crypt is contrasted between being open (hatched line) or closed to the luminal enema fluid (see further details in text).
David F. Katz (457242), Yajing Gao (376525)   +1 more
core   +1 more source

Probenecid‐Boosted Tenofovir: A Physiologically‐Based Pharmacokinetic Model‐Informed Strategy for On‐Demand HIV Preexposure Prophylaxis

CPT: Pharmacometrics & Systems Pharmacology, 2020
Multiple doses of tenofovir disoproxil fumarate (TDF) together with emtricitabine is effective for HIV preexposure prophylaxis (PrEP). TDF is converted to tenofovir (TFV) in circulation, which is subsequently cleared via tubular secretion by organic ion ...
Stephanie N. Liu, Zeruesenay Desta, Brandon T. Gufford   +2 more
doaj   +1 more source

Perspectives on the utility and interest in a point-of-care urine tenofovir test for adherence to HIV pre-exposure prophylaxis and antiretroviral therapy: an exploratory qualitative assessment among U.S. clients and providers

AIDS Research and Therapy, 2020
Background Real-time, objective measures of adherence to antiretroviral therapy (ART) and pre-exposure prophylaxis (PrEP) are needed to better assess adherence levels and to expedite clinical response for those with suboptimal adherence.
Ashley R. Bardon, Jane M. Simoni, Leif M. Layman, Joanne D. Stekler, Paul K. Drain   +4 more
doaj   +1 more source